J

Jacobs Solutions Inc. Releases Pro Forma Financials

The unaudited pro forma consolidated financial information of Jacobs Solutions Inc. has been released, reflecting the impact of the separation and distribution of its Critical Mission Solutions business and portions of the Divergent Solutions business to Amentum Holdings, Inc. (SpinCo). The following figures provide a comparison between the historical financials and the pro forma adjustments.

As of June 28, 2024: Cash and cash equivalents decreased from $1,208,661 to $1,012,747 after the separation and distribution. Accounts receivables and contract assets decreased from $3,774,227 to $2,696,769. * Goodwill decreased from $7,404,867 to $4,740,769.

Nine Months Ended June 28, 2024: * Revenues decreased from $12,659,898 to $8,541,300 after the separation.

Year Ended September 29, 2023: * Revenues decreased from $16,352,414 to $10,839,329 after the separation.

Year Ended September 30, 2022: * Revenues decreased from $14,922,825 to $9,783,853 after the separation.

Year Ended October 1, 2021: * The impact of the separation on this period is not provided in the available information.

The unaudited pro forma consolidated financial information is presented to reflect how the separation and distribution might have affected the historical financial statements had the transactions been consummated at an earlier date. It is important to note that the figures are for informational purposes only and do not purport to show the results that would have occurred had such transactions been completed as of the date and for the periods presented or which may occur in the future.

Please note that the financial information is forward-looking and is subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated. As a result of these announcements, the company's shares have moved 0.8% on the market, and are now trading at a price of $130.88. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS